News and Events

The blood that runs in depression

Researchers at i3S have developed a method that may help diagnose depression through blood tests. In the near future, MyRNA will create a kit that promises to contribute to a happier world.

For additional information, please visit the link

ARNanoFilm on the news!

ARNanoFilm technology comprises the incorporation of antiretroviral drug-loaded nanoparticles into thin polymeric films. These systems are intended to be placed in the vagina in order to prevent male-to-female sexual transmission of HIV. It is expected that drug-loaded nanoparticles-in-films may provide enhanced safety and efficacy as compared to more conventional formulations previously tested in clinical trials. The major goal of the ARNanoFilm project is to empower women worldwide with a novel option for protection against HIV/AIDS.

Since November 2016 Symbiosis has been part of the RESOLVE program.
For additional information please visit the online dissemination on the following links:,579b8779-547d-406e-85d0-2b528ca0b3f7.html

i3S-Hovione Health Innovation Prize

3S and Hovione Capital are glad to announce an ​I​nternational ​A​ward aiming at distinguishing innovative ideas in the health sector. The deadline for applications is the 7th of September, and the prize will be announced on the 28th of September.  

For additional information, please visit

SkinLesionRS on the news!

Skin cancer corresponds to 1/3 of all cancers and malignant melanoma is responsible for most skin cancer deaths. The SkinLesion technology targets this problem by enabling general practitioners in local health centers to perform a skin screening procedure according to the DGS’s Dermatological Telescreening norm, and do so with a much increased efficiency and reduced error rate. It thus greatly facilitates the referral process and ensures dermatologists receive relevant data for triage. On top of that, it offers further support through its automatic melanoma risk assessment tool.

Since April 2017 SkinLesion from Fraunhofer Portigal has been part of the RESOLVE program.
For additional information please visit the online dissemination on the following links:

Symbiosis on the news!

The re-emergence of tuberculosis (TB) associated with modern epidemics and immune therapies threatens the progress made in controlling this disease. Tailor-made interventions are needed to tackle the many faces of TB, in particular the transition from latency to infectious, active disease. Developing molecular-based point-of-care tests to stratify the estimated 2 billion latently infected individuals for their risk of reactivation would allow focusing treatment on those at higher risk, considerably reducing the number of people undergoing preventive antibiotherapy and the toxic side effects associated with it. Based on previous research from the involved teams, Symbiosis addresses a rapid diagnostic test for risk stratification of latent TB.

Since April 2017 Symbiosis has been part of the RESOLVE program.
For additional information please visit the online dissemination on the following links:

RUBYnanomed on the news!

Metastatic disease is directly responsible for most of cancer-related deaths worldwide. Circulating tumor cells (CTCs) shedding from the primary tumor have the ability to invade other organs, causing metastasis. Their study allows continuous and real-time monitoring of metastatic cancer progression based on a low invasive sampling in cancer patients, constituting the so-called liquid biopsy.
EasyBiopsy enables liquid biopsy for metastatic cancer at the point-of-care. It uses a proprietary cell microfluidic capture tool that can be used for early cancer metastasis detection, better prognosis and personalized treatment.

Since November 2016 RUBYnanomed has been part of the RESOLVE program.
For additional information please visit the online dissemination on the following links:

Facegram on the news!

Facegram is proposed as a new standard and a universal tool for detailed analysis of facial movements in the context of therapy, surgery and rehabilitation of the face. It is presented as a new strategy to compile and visualize morphometric data, including a set of distilled measurements with clinical usefulness that can be easily interpreted by a physician. Just as a cardiogram or an audiogram are crucial medical tools to assess heart or hearing disorders, the Facegram compiles precise and objective quantitative measures regarding facial static and dynamical properties.
Since April this year Facegram has been part of the RESOLVE program.
For additional information please visit the online dissemination on the following links:

ProREGEN on the news!

Spinal cord injury (SCI) affects over 200.000 patients worldwide every year. Despite considerable progress in the medical, surgical, and rehabilitation of SCI patients, there are no effective treatments improving neurologic outcome. Thus, it is essential to identify translatable therapies favouring axon regrowth and spinal cord repair. Our goal is to evaluate the in vivo regenerative potential of constitutively active Profilin-1 (Pfn1) after lesion. Our data demonstrates that in vitro delivery of Pfn1 is a robust enhancer of axon growth with an unprecedented effect in the field. If successful, this therapy could be applicable to other conditions where axon regeneration is needed.
Since April this year ProREGEN has been part of the RESOLVE program.


For additional information please visit the online dissemination on the following links:

VRCare on the news!
VRCare will be the first Virtual Reality Medical Device for the Treatment of Anxiety Disorders that every Mental Health Professional can use with success. VRCare provides scientifically tested Virtual Reality Exposure Therapy protocols, combined with advanced biofeedback technology and dynamic 3D environments.
Since April this year VRCare has been part of the RESOLVE program, combining efforts with the i3S team.
Worldwide Accelerator Rally at Porto

Two months ago, through the ScaleUp Porto project, the City Council invited the entrepreneurial community to propose activities that reflect the vitality of the city's ecosystem, attributing new dynamics to it in terms of technology and innovation. For this purpose, it provides 70 thousand euros. From dozens of applications received, eight projects were selected, which by the end of this year will inspire the city and its entrepreneurial spirit. 

The selected proposals begin to be implemented already in the current month and run until 31 December 2017.

One of the selected projects was WARP - Worldwide Accelerator Rally at Porto - organized by the RESOLVE Team. 

Conference in the area of ​​innovation and entrepreneurship in the biomedical sector, with speakers of national and international notoriety. In parallel, on the same day, an International Biomedical Technology Exhibition will be organized, including stands to expose the technologies that are supported in all editions of the RESOLVE Program, as well as national and international technologies / teams supported by other accelerators, and all innovative technologies intending to participate in the event. 

Stay tunned!!

Teamwork makes the dream work

RESOLVE Team wants to aknowledge all the team projects that were present in the RESOLVE tecHospital event for their amazing performance showing their projects and prototypes. We want also to aknowledge all the guests and participants that showed their interest and important feedback in the event. It was a real sucess! Thank you. 

For additional information please visit the online dissemination on the following links:

RESOLVE tecHospital - Scale up Porto

No âmbito da semana Start&Scale Porto, o Programa RESOLVE convida toda a comunidade da cidade para o evento RESOLVE tecHospital, a realizar no dia 2 de Junho das 14.00h às 17.00h nas instalações do i3S – Instituto de Investigação e Inovação em Saúde (Rua Alfredo Allen, 208, Porto).

O evento RESOLVE tecHospital pretende expor e demonstrar os projetos que tem vindo a promover entre 2016 e 2017 num formato inovador, de Hospital do Futuro, apresentando tecnologias inovadoras para as diversas especialidades médicas.


EasyBiospy (Dispositivo de Isolamento de células tumorais circulantes),

OncoAdvanC+ (Novos compostos para tratamento do cancro do intestino),

GlycoTarget (Anticorpos Diagnósticos e terapêuticos para o cancro do estômago),

SkinLesion (Tecnologia Digital da Fraunhofer para rastreio de melanoma),


HECOLCAP (Biomaterial para preenchimento preventivo de infecções ósseas),

Adapttech (Start-up com solução para adaptação de próteses),


Symbiosis (Sensor point-of-care para a Tuberculose recorrente)

ARNanoFilm (Película para administração profiláctica de anti-retrovirais)


ProREGEN (Regeneração de fraturas da espinal-medula)

VRCare (Realidade Virtual para o medo de voar)


SurgeonMate (Óculos de gravação de cirurgias)

Facegram (Tecnologia de monitorização de cirurgia reconstrutiva)


Glucodii (Novos compostos para evitar o agravamento dos sintomas das doenças inflamatórias intesntinais)

BestHealth (Adesivos e dispositivos para ostomizados)

Infeccção Hospitalar:

AntiBioCoat (revestimento antibacteriano para cateteres)

Pathowatch (Solução de metagenómica para monitorização da Infeção Hospitalar)

O RESOLVE é um Programa de ignição na área da saúde para apoio à transferência de conhecimento científico e tecnológico de projetos inovadores promissores em estágio inicial. Estes projetos têm o potencial de se traduzir em soluções para o benefício do doente e dos profissionais de saúde, respondendo a desafios societais prementes. O RESOLVE, baseado no i3S, apoia estes projetos pela aplicação e implementação de 7 ferramentas desenhadas para necessidades especificas, tanto em termos de tecnologia como em termos de estratégia de mercado: (1) Voucher para Validação de Provas de Conceito e Protótipos; (2) Fórum com utilizadores finais; (3) Via verde para estudos clínicos; (4) Integração de alunos de MBA; (5) Observatório de Plataformas de Open Innovation (6) Lista de contactos para licenciamento e (7) Encontros com Investidores.

3-D-printed scaffolds restore ovary function

In a new study, researchers use 3-D printing to make a porous ovary scaffold and seed it with immature egg-producing cells. They show that infertile mice implanted with the engineered ovary are able to ovulate, mate, and give birth to and nurse healthy pups in the normal way. The study is the first to achieve such a result with the help of 3-D printing, and it shows how using the technology to fine-tune the pore architecture of the scaffold is key to success.

Innovative antibody based vaccine

Researchers from i3S, Porto have developed a vaccine that helps to prevent bacterial infections that cause diseases such as meningitis, pneumonia, septicemia and, in the most critical cases, death from septic shock.

The bacteria that cause these pathologies (Klebsiella pneumoniae, Escherichia coli, Group B Streptococcus, Streptococcus pneumoniae and Staphylococcus aureus) are very resistant strains and cause "a huge problem for public health" said Pedro Madureira, a researcher at the Institute for Research and Innovation in Health (i3S) at the University of Porto to Lusa.

"From the moment these bacteria infect the host [individual], they are able to release a molecule (a protein called GAPDH)," which renders them "invisible" to the immune system, "thus preventing the onset of an immune response" explained the scientist, one of the founders of the company Immunethep, responsible for the creation of the vaccine.
Without a proper response of our immune system, bacteria "rapidly proliferate" in the bloodstream and in the infected organs, which can lead to such pathologies, considered "quite severe".
"Although this vaccine is intended for all people", there are individuals in whom the "incidence of this type of infection is greater", such as newborns, the elderly, patients with type I diabetes, patients undergoing invasive surgery or with obstructive pulmonary disease, for example.

"The investigator considers this vaccine to be "innovative" since instead of inducing an immune response (production of antibodies) against the bacteria itself, it does induce a single molecule neutralizing response (GAPDH) released by bacteria, allowing the immune system to control the different infections.
The vaccine, which has already undergone laboratory tests with rats and rabbits, will move to the clinical trials phase I in the last quarter of 2017, predicts the researcher.
According to Pedro Madureira, in addition to the vaccine, Immunethep is developing a form of therapy based on monoclonal antibodies, which neutralize the GAPDH protein, and can be used in people already infected and for whom there is no time for vaccination.
"These antibodies have the advantage over the vaccine of acting very fast and the disadvantage of not inducing 'immune memory'", which is associated with the ability of our immune system to, after first contact with a foreign agent, "Trigger a much faster and more efficient response" he explained.
Pedro Madureira also spoke about the importance and history of vaccines, in order to "demystify" some uncertainties about vaccination, and also about this being the "great achievement of immunology and medicine." The vaccine "is something that works" being this the clinical approach that "best results have brought to humanity," he said.

Nanovacin against different cancers

Researchers from the University of Texas in the United States have developed nanovacin (a vaccine given through microscopic particles) against different cancers, such as skin, colon and rectum in rat models studies. 

Nanovacins consist of tumor proteins that can be recognized by the immune system and are inside a synthetic polymer nanoparticle. The tiny particles are directed to the target, stimulating the immune system to trigger a response against aggressive agents such as tumors. The idea is to help the body fight cancer with its own defenses.

The researchers studied a variety of tumors associated with cancers of the skin, colon, rectum, uterus, head and neck. The study was published in the journal Nature Nanotechnology. 

In most cases, nanovacin slowed down tumor growth and extended animals lifespan. The experimental nanovacin activated the adapter protein STING, allowing the stimulation of the immune defense of the organism of the rodents against the cancer.

Other vaccine production technologies have been used in immunotherapy against cancers but have higher production costs and are more complex because they involve live bacteria or multiple biological stimulants, says the University of Texas.

The team of scientists is working with doctors to administer nanovacin to cancer patients. According to the researchers, combining nanovacins with radiotherapy or other immunotherapies may in the future increase the effectiveness of cancer treatments.

What are parents' concerns about vaccinations?

"Parents have three major reasons, one is that they think that vaccines are no longer needed and the diseases are gone, the second is that they fear that the vaccines are associated with adverse reactions, and third [is that] they think that they should be able to decide what their children should receive and not have to be mandated to receive vaccines for school or other requirements," Dr. Kathryn M. Edwards, the Sarah H. Sell and Cornelius Vanderbilt Chair in Pediatrics at the Department of Pediatrics and Infectious Diseases at Vanderbilt University School of Medicine in Nashville, TN, told Medical News Today.
"Physicians need to clearly point out the benefits of the vaccine and tell them that vaccines are the standard of care for children. They have made an enormous difference in the lives of children. No longer do children die of meningitis, measles, and pneumonia since the widespread use of vaccines. Just like pediatricians should stress the use of car seats when children ride in cars, they need to stress the important role of vaccines in assuring child health" says Dr. Kathryn.
Employing motivational interviewing techniques is another way of approaching a vaccine-hesitant parent, and this involves parents verbalizing their concerns and the physician giving focused answers. Ideally, this interaction should allow the parent and patient to self-reflect and ultimately come to a place of understanding of the benefits of vaccination on their own.

RESOLVE Program in ECO online

With 22 active patents and six projects, i3S decided to take a step forward and launch Resolve. The first call of the program was launched on May 1, 2016. It aims to atract researchers from around the world who want to set up their research project in Oporto - seven projects, including two spin-offs, are already being supported. The selection process goes through an online registration, by completing an application form.

The final phase of the selection process involves a jury outside the i3S, explains the person in charge."An interesting step is that we have a diagnostic process right there: these external juries produce a short report of what they think is the team's great needs and also what do they think will be the necessary tools to mature the project. They make us a previous diagnosis of the team. This will be important to develop a roadmap in each the project and resolve teams will work in collaboration during 12 months of support. 

After the necessary development, Resolve supports researchers, whether they choose the licensing of start-up cration path. "Our [i3S] patents on licensing or already sold have yielded several millions. In Resolve Program, the choice is made by analyzing the most appropriate way for the team and for the technology, because we believe that not all researchers need ot want to be entrepreneurs."says João.

For additional details on this news, please click here. 

Seeking innovative "cure" for baldness

The Institute for Research and Innovation in Health (i3S) and Clínica Saúde Viável recently established a partnership with the goal of revolutionizing capillary health. In a clear relationship between the private clinical sector, biology research and applied research in bioengineering, the idea of ​​this protocol is to develop stem cell research in hair follicles with a view to baldness resolution.

"This is a cutting-edge research project. It is intended to develop stem cell research that, by allowing the multiplication of follicles, can eliminate a huge problem that affects women and men around the world, "adds Paulo Ramos, administrator of the Clínica Saúde Viável. 

According to the World Health Organization (WHO), more than 50% of the male population will suffer from baldness until the age of 50. There are also studies that associate accentuated hair loss with psychological complications, namely anxiety and depression.

5 days left to apply!

The Institute of Research and Innovation of the University of Porto (i3S) announced RESOLVE's program second call. Proposals will be held until 27 March.


The program aimed to promote health technologies with potential market interest and is open to the whole country, providing project implementation in the North of Portugal. For two years, RESOLVE will finance a minimum of ten projects up to 75,000 euros each. On the first call the program received 26 applications and there are already seven teams receiving support. Selected applications include technologies for amputees, catheter coating to prevent nosocomial infection, detection of circulating tumor cells or bone implants, among others.

Roadshow INESC TEC - 13th March

To announce the opening of the second call to the RESOLVE Program, there will be a Program Presentation session, which will take place on March 13th at 2:00 pm in the Auditorium A of INESC TEC.

RESOLVE is an ignition program, designed for the promotion of seed projects and health start-ups ( The goal of the RESOLVE Program is to promote knowledge transfer by providing support and management tools, including financial support for seed projects of researchers and entrepreneurs in this sector.

Second call open until 27 March 2017 (6:00 pm).

14h00 – Opening Session – José Manuel Mendonça, Chairman of the Board of Directors INESC - TEC
14h15 - War Story – to be announced
14h30 – RESOLVE Program Presentation
15h00 - Roundtable
· João Claro, INESC – TEC, Carnegie Mellon Portugal 
· Miguel Velhote, Kinematix, INESC – TEC
· Pedro Almeida, Fraunhofer
. Katiuska Cruz, ANI
16h00 – Closing session and Coffee Break
Registration at:

Roadshow Braga - 10th March

To announce the opening of the second call to the RESOLVE Program, there will be a Program Presentation session, which will take place on March 10th at 2:00 pm in the Auditorium of School of Engineering, Campus de Gualtar

RESOLVE is an ignition program, designed for the promotion of seed projects and health start-ups ( The goal of the RESOLVE Program is to promote knowledge transfer by providing support and management tools, including financial support for seed projects of researchers and entrepreneurs in this sector.

Second call open until 27 March 2017 (6:00 pm).

14h00 – Opening Session – Eugénio Ferreira (Director of the Center for Biological Engineering - CEB)
14h15 - War Story – Jorge Correia-Pinto (iSurgical3D)
14h30 – RESOLVE Program Presentation
15h00 - Roundtable
· Lígia Rodrigues (Biotempo, CEB/UM)
· Jorge Maia Gomes (Innovation and Strategic Planning, Hospital de Braga)
· Luísa Pinto (Bn’ML – Behavioral & Molecular Lab, ICVS)
16h00 – Closing session and Coffee Break
Registration at:

Roadshow ICBAS - 2nd March

To announce the opening of the second call to the RESOLVE Program, there will be a Program Presentation session, which will take place on March 2nd at 2:00 pm in the ICBAS / FFUP Hall.

RESOLVE is an ignition program, designed for the promotion of seed projects and health start-ups ( The goal of the RESOLVE Program is to promote knowledge transfer by providing support and management tools, including financial support for seed projects of researchers and entrepreneurs in this sector.

Second call open until 27 March 2017 (6:00 pm).

14:00 - Opening of the event by representative of ICBAS / FFUP
14:15 - "War Story" - Pedro Madureira (Immunethep)
14:30 - Presentation of the RESOLVE Program
15:00 - Round table - "Integration of ignition / acceleration programs in the innovation ecosystem"
> Salomé Pinho, (Glyco4Clinics, i3S, 1st Edition of the RESOLVE Program)
> André Faustino (GenePredit)
> Cristina Freire (INNOVCAT, FCUP)
16:00 - Closing and Coffee Break

Registration at:


Founder from FCUP wins Tech Challenge

Women Who Tech,a nonprofit organization working to break down barriers to women in the tech industry, announced the winners of the Women Startup Challenge VR and AI. The "Shark Tank-style" competition was held before an audience of tech industry executives at Google's New York campus in Chelsea.

"We are grateful to Women Who Tech for believing in our mission and helping bring Didimo to the whole world. It was an exciting night, preparing the pitch for the event was enriching, and we were given the opportunity of sharing why we build Didimo with everyone. It has been an honor to share the stage with other amazing companies," said Didimo Cofounder Veronica Orvalho.

Didimo of received the grand prize -- a cash grant of $50,000 from the Craig Newmark Philanthropic Fund as well as $15,000 in legal services from Paul Hastings LLP.  Didimo automatically creates 3D virtual characters from a single photo; in about 2 minutes it creates a lifelike avatar that can speak, move, and represent you in a 3D world. Platform agnostic and compatible with all 3D environments, their technology can be used in games, social media, film, AR, and VR.


If you have a seed project coming from R&D institutions or a Start-up in the Health sector, we have created a TOOLBOX to add value to your technology! Apply until 27th March at

Ready to Jump?

ReadyToJump? Join @Startup Porto Accelerator and pitch, pitch, pitch to sell more and get funded.
Apply at

UPTEC's Pitch Day winner

The winner of the Pitch Day of the 8th edition of the Startups School of UPTEC - Science and Technology Park of the University of Porto was WeStoreONTEX, a project that develops flexible textiles and accessories that store energy to power electronic devices and sensors integrated into clothing.
For the honorable mention in the biotechnology area, the jury chose the individual protective glasses for surgeons with integrated capacity to make multimedia records of the operative acts, created by SurgeonMate.
The challenge presented to the authors of the 17 projects was to present business ideas in 180 seconds, and the winner will get six-month incubation period at UPTEC, 20 hours free legal advice from CCA Ontier and a Microsoft Surface Pro tablet.

Team Building with MBAs

The public presentation of the teams from RESOLVE 1st Edition to the students from Porto Business School (PBS) was a real success! The teams presented their projects in a pitch format and caught the attention and enthusiasm of the MBA students!

See the photos!

Innovative therapy for Ulcerative Colitis

A new treatment for patients with Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease) will be tested for the first time in clinical trials in Portugal with the support of an American foundation, Crohn's & Colitis Foundation of America - CCFA, through the its Medical Research Program (BMRP). The project is led by Salomé Pinho, a researcher at the Institute of Research and Innovation in Health (i3S) at the University of Porto and will be developed at the Porto Hospital Center/ Santo Antonio Hospital in collaboration with other national hospitals, such as the S João Hospital, also in Porto.

The research coordinated by Salomé Pinho aims to test in a clinical trial a novel agent, of natural origin, non-toxic, low cost and with immuno-modulating properties. This compound was previously tested in pre-clinical trials demonstrating efficacy in controlling intestinal inflammation and suppressing the progression and severity of the disease. In a first phase the study will be national, but it is envisaged to be extended to other European hospitals.

"With this clinical trial we intend to evaluate the therapeutic effect of the new agent in patients with Ulcerative Colitis by assessing its effect on disease control and reducing the need for more aggressive therapies, surgeries and hospitalizations," explains Salomé Pinho, who has devoted a large part of her research to the study of Inflammatory Bowel Disease.

Biosimilars and the sustainability in health systems

The European Society of Medical Oncology considers that biosimilar medicines are "indispensable weapons" for the treatment of cancer in health systems that are intended to be financially sustainable
Biosimilars are medicinal products from living organisms similar to other biological medicinal products that have already been authorized to enter the market. Although similar, the development process is more complex than for generics. Biosimilars require clinical studies to ensure that the manufacturing process is correct.
In Europe, price reductions for biosimilars should range between 20% and 40%, with potential savings of EUR 50-100 billion by 2020 from these medicines.

5 life-changing innovations

IBM researchers revealed their five big predictions for innovations that will change our lives in the next five years. Dubbed IBM 5 in 5, the predictions were culled from more than 3,000 researchers across 12 labs on six continents.
These predictions focus on the future of artificial intelligence and mental health, AI-based superhero vision, macroscopes that capture the Earth’s complexity, medical labs on a chip, and smart sensors that will detect environmental pollution. Innovations in these areas could enable us to dramatically improve farming, enhance energy efficiency, spot harmful pollution before it’s too late, and prevent premature physical and mental health decline.
“The scientific community has a wonderful tradition of creating instruments to help us see the world in entirely new ways. For example, the microscope helped us see objects too small for the naked eye and the thermometer helped us understand temperature of the earth and human body,” said Dario Gil, vice president of science and solutions at IBM Research, in a statement. “With advances in artificial intelligence and nanotechnology, we aim to invent a new generation of scientific instruments that will make the complex invisible systems in our world today visible over the next five years.”
The IBM 5 in 5 is based on market and societal trends as well as emerging technologies from IBM’s research labs around the world that can make these transformations possible. (Additional information)

Portuguese drug tested successfully

Luzitin’s Redaporfin treatment is a novel combination therapy which is applicable to virtually all solid tumors accessible to minimally invasive illumination with its optical fibre laser light source.
The first phase of the trial was carried out in Porto, at the Portuguese Oncology Institute (IPO) and CUF Hospital, with a group of volunteer patients and with the objective of evaluating the safety (tolerance) and antitumor (efficacy) effect of Redaporfin,that had already demonstrated great efficacy in non-clinical trials in animal models.
"The trial was performed on a restricted group of patients, who recorded very interesting results and proved that the drug is safe and does not trigger severe side effects" explained Sérgio Simões, president of Luzitin.
The  responsible for the clinical trial, Lúcio Lara Santos (IPO Porto), explained to Agência Lusa that this remarkable step in the treatment of head and neck cancers opens the possibility of treatment for other solid tumors.
This trial will go down in the history of Portuguese clinical pharmacology as the first "entry-into-Man" trial of an oncology product held in Portugal.


Technology to prevent elderly falls

The Fraunhofer Portugal AICOS Research Center in Porto is developing a technology that involves traditional dance and tai chi and allows the elderly to train their strength and balance at home, preventing the occurrence of falls.
The program, designed for use at home by an equipment connected to the television and a set of four sensors, placed on the arms and legs, can help the elderly in the prevention of falls which, according to the research center, is responsible for 50% of hospitalized elderly patients.
This is a project that aims to "promote physical activity in the elderly," and these modalities were chosen by the "entertainment and entertainment component that are Associated ", said the project manager António Santos.
At this moment the technology is being validated by the seniors of the Network Colaborar, a group of about thousand seniors who participate voluntarily in the validation of the technologies developed by Fraunhofer Portugal AICOS.
The volunteers of this network have tested the technology in LivingLab, a laboratory of the Center, created in 2011. This LivingLab constitutes a "welcome space" for volunteers since they are "very important in the testing and validation of The technology "developed, said the researcher Inês Sousa.

Additional information:

The inventive spirit of Félix Carvalho

Félix Carvalho is a professor and researcher at the Faculty of Pharmacy, University of Porto (FFUP).

The innovative and enterprising side of Félix Carvalho, reconciled with the effort to generate knowledge and training of students, is one of the major reasons for classify him as an inventor at the University of Porto. "Since 2004 the U.Porto has been stimulating the inventive spirit of its researchers through unprecedented, well-established support with dissemination actions, entrepreneurship courses, promotion of knowledge transfer, support in industrial property registration and reinforcement of Linking the University to companies, through U.Porto Innovation "he says. For this reason, and despite recognizing some shortcomings, especially in terms of support for graduate students, Félix Carvalho does not hesitate to say that being part of the U.Porto family, and taking advantage of what the ecosystem gives researchers, "allows the necessary change of mentality that makes everyone look at the research in a different way. "

The project in which the Félix Carvalho is currently working and has already been tested in laboratory animals, is the development of an antidote to treat poisonous mushrooms poisoning. The species that FFUP team studied is called Amanita phalloides, or "death hat" and has been "responsible for 90-95% of the deaths from poisonous wild mushrooms for which no effective antidote existed" explains the teacher. Worried about these numbers, Félix Carvalho has been dedicated to looking for an antivenom through "inhibiting the coupling of toxins from these same mushrooms to an enzyme that is responsible for the transcription of our DNA" he explains. The tests performed in the meantime have been able to find an effective antidote when given early, although some protection diminishes at a later stage after intoxication. For this reason, the team coordinated by Félix Carvalho is currently focused on perfecting the treatment, to make it effective "even in extreme cases where the patient takes too long to arrive at the hospital" he concludes.



Merry Christmas

The RESOLVE team wishes you a Merry Christmas and an inspiring New Year!​

50 innovative treatments - INFARMED

By the end of the year, 50 innovative treatments will be approved in Portugal, of which 20% aiming to fight cancer. According to INFARMED, this is the largest number of drugs approved since there are records. 
"More than 40 innovative drugs are now approved. Ten are already finished for the oncology field. Breast and lymphoma, among others. By the end of the year, there will be 50 approvals. It will be the largest number since there are records in INFARMED (2007), "said Henrique Luz Rodrigues, president of INFARMED, who participated in the debate" Cancer 2020 - We can do even better. "

According to the National Drug Authority, in three months it was possible to reduce the delays in the approval of medicines, following the creation of a Commission of Health Technology Assessment, which has a hundred experts.

Health technology assessment model

The Portuguese Institute of Oncology of Porto has developed a health technology assessment model that aims to ensure that system resources, particularly financial resources, provide the maximum health benefits.

The Cancer Value Label model allows, for example, to verify "how a drug behaves in certain dimensions, particularly in relation to the issue of quality of life, and then compare the results with the price", said Rocha Gonçalves, member of the board of directors of IPO-Porto and responsible for the project.

Rocha Gonçalves said that this model "is innovative, since there was no assessment model of health technologies 100% Portuguese. This is a satisfaction for us, we have managed to produce the first model and on the other hand it is innovative because it incorporates added-value dimensions that current in use models still do not incorporate."

For additional information please see the link

Tecnifar awarded ICBAS epilepsy research

Tecnifar SA awarded a research grant in epilepsy to the project "“Fatores epigenéticos: Possíveis Biomarcadores de Epileptogénese?", whose clinical team is headed by João Chaves from the Neurology Service of the University Hospital Center of Porto (CHUP). Laboratory team is directed by Maria Berta Silva, researcher at the Laboratory of Immunogenetics of the Institute of Biomedical Sciences Abel Salazar (ICBAS) of the University of Porto.
As a final objective, it is expected that new strategies for the pharmacological control of seizures and for the prevention of epilepsy can be developed.

Visit of King of Spain to the i3S

For the King of Spain, "it is the University of Porto and its Science and Technology Park that make Oporto an entrepreneurial city of excellence, helping to boost the economy and attract more and more companies." This tuesday, the kings visited the Technology Park of the University of Porto (UPTEC) and the Institute of Research and Innovation in Health (i3S), two institutions where they could meet some of the projects developed at the University in the areas of innovation and entrepreneurship. At i3S, Felipe VI and Letizia had a private meeting with the Board of Directors and the coordinators of the three research programs (Cancer, Interaction and Host Response and Neurobiology and Neurological Diseases) of the institute. This was followed by a visit to the Department of Histology and Electron Microscopy and to the Laboratory of Biomaterials for Multi-Stage Release of Drugs and Cells, specialized in the development of biomaterials for the regeneration of tissues, as well as diagnosis and treatment of cancer. 

"It is remarkable the huge number of public and private Research Centers with headquarters in Oporto, which have agreements with the most diverse Spanish and international institutions", Felipe VI also considered.

Salomé Pinho awarded with ECCO prize

ECCO - European Crohn's and Colitis Organization recently awarded with a prize of 40 thousand euros a proposal from the researcher of i3S Salomé Pinho to carry out pre-clinical trials aiming to find a new therapeutic strategy for Inflammatory Bowel Disease (IBD).

It is a disease that affects about 2.5 million inhabitants in Europe, with incidence increasing worldwide, including in Portugal. The fact that this financial support is of a European organization of great prestige and reputation in the international sphere, emphasizes Salomé Pinho, "makes this prize a reason of great personal pride, but above all a stimulus for the research team that integrates the project. The mission of our research team is to use a multidisciplinary approach, from fundamental research to pre-clinical and clinical validation of rational therapeutic strategies for inflammation and in particular for IBD."

This project is a result of the collaboration between the i3S and the gastroenterology department of the Centro Hospitalar do Porto / Hospital de Santo António(CHP), in particular with the DII unit, coordinated by Paula Lago.

2Bio supports RESOLVE Program

2Bio’s Impact Science will be supporting the RESOLVE Program in Northern Portugal to develop and nurture early stage projects and start-ups in the health technology sector.

2Bio’s Director, Dr. Rhys Roberts, whose company has an international client base, commented “there is now a global demand for new ideas and products that will improve the standards of healthcare, and also make it more affordable to deliver; the RESOLVE approach to identifying and shaping commercial opportunities at an early stage should result in a much stronger offering for investors and for the growing global healthcare technology sector.

For additional information please see the link.

The first RESOLVE Partners and Sponsors

The RESOLVE Team is glad to announce the first 15 Partners and Sponsors ( This entities will be closely involved in assisting the selected projects in the application of the RESOLVE Toolbox. 

Autophagy Pioneer Wins Nobel

Yoshinori Ohsumi, an honorary professor at the Tokyo Institute of Technology, has won the 2016 Nobel Prize in Physiology or Medicine. Ohsumi is recognized for his discoveries on the mechanisms of autophagy, the process by which a cell recycles unnecessary components (see Ohsumi Lab, Toky Institute of Technology). 

Applications are open until 2 November

The RESOLVE Program was sucessfully launched on the 15th of September, with the presence of more than 100 attendees. The call for applications is now open until the 2nd of November, 2016 (19:00). Apply now through For any clarification, please contact

Kick-off RESOLVE Program

The official kick off of the RESOLVE Program will take place on September 15, 2016 between 14h and 16h in the Corino de Andrade auditorium at i3s - Institute for Research and Innovation in Health (map).

If you would like to attend, for logistics purposes, please confirm your presence by September 12 to

Join us!

RESOLVE awards

The RESOLVE Program will award two prizes from 5000€/each:
Best Innovation Project to the best Researcher(s)/Start-up Team.
Best Business Case by MBA Team to the best MBA Team

Scientists Invent Oxygen Particle That If Injected, Allows You To Live Without Breathing

A team of scientists at the Boston Children’s Hospital have invented what is being considered one the greatest medical breakthroughs in recent years. They have designed a microparticle that can be injected into a person’s bloodstream that can quickly oxygenate their blood. This will even work if the ability to breathe has been restricted, or even cut off entirely.

This finding has the potential to save millions of lives every year. The microparticles can keep an object alive for up to 30 min after respiratory failure. This is accomplished through an injection into the patients’ veins. Once injected, the microparticles can oxygenate the blood to near normal levels. This has countless potential uses as it allows life to continue when oxygen is needed but unavailable. For medical personnel, this is just enough time to avoid risking a heart attack or permanent brain injury when oxygen is restricted or cut off to patients.

For additional information, please see


RESOLVE Open Calls

Do you have an innovative technology in the health sector?

Submission of applications to the RESOLVE Program are now OPEN to seed projects, based or to be based in the North of Portugal, coming from R&D Institutions and/ or companies from the Health Sector. Apply now!